GENFIT (GNFT), a late-stage biopharmaceutical company developing drugs for rare and life-threatening liver diseases, has a regulatory catalyst to watch this quarter.The company's investigational drug Elafibranor, proposed for the treatment of primary biliary cholangitis, is under priority review by the FDA, with a decision due on June 10, 2024.Genfit signed an agreement in December 2021, giving Ip...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.